1. Home
  2. PBMWW vs ELMD Comparison

PBMWW vs ELMD Comparison

Compare PBMWW & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • ELMD
  • Stock Information
  • Founded
  • PBMWW N/A
  • ELMD 1992
  • Country
  • PBMWW Canada
  • ELMD United States
  • Employees
  • PBMWW 10
  • ELMD N/A
  • Industry
  • PBMWW
  • ELMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • PBMWW
  • ELMD Health Care
  • Exchange
  • PBMWW Nasdaq
  • ELMD Nasdaq
  • Market Cap
  • PBMWW N/A
  • ELMD N/A
  • IPO Year
  • PBMWW N/A
  • ELMD 2010
  • Fundamental
  • Price
  • PBMWW $0.02
  • ELMD $27.73
  • Analyst Decision
  • PBMWW
  • ELMD
  • Analyst Count
  • PBMWW 0
  • ELMD 0
  • Target Price
  • PBMWW N/A
  • ELMD N/A
  • AVG Volume (30 Days)
  • PBMWW N/A
  • ELMD 92.7K
  • Earning Date
  • PBMWW N/A
  • ELMD 02-11-2025
  • Dividend Yield
  • PBMWW N/A
  • ELMD N/A
  • EPS Growth
  • PBMWW N/A
  • ELMD 94.54
  • EPS
  • PBMWW N/A
  • ELMD 0.72
  • Revenue
  • PBMWW N/A
  • ELMD $57,060,000.00
  • Revenue This Year
  • PBMWW N/A
  • ELMD $14.27
  • Revenue Next Year
  • PBMWW N/A
  • ELMD N/A
  • P/E Ratio
  • PBMWW N/A
  • ELMD $38.26
  • Revenue Growth
  • PBMWW N/A
  • ELMD 14.73
  • 52 Week Low
  • PBMWW N/A
  • ELMD $9.81
  • 52 Week High
  • PBMWW N/A
  • ELMD $31.31
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • ELMD 48.70
  • Support Level
  • PBMWW N/A
  • ELMD $26.91
  • Resistance Level
  • PBMWW N/A
  • ELMD $28.98
  • Average True Range (ATR)
  • PBMWW 0.00
  • ELMD 1.22
  • MACD
  • PBMWW 0.00
  • ELMD -0.45
  • Stochastic Oscillator
  • PBMWW 0.00
  • ELMD 21.93

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: